BofA downgraded Biohaven (BHVN) to Neutral from Buy with a price target of $10, down from $49, after the company announced that the FDA issued a complete response letter for its troriluzole application for the treatment of spinocerebellar ataxia. The firm believes the pathway forward is “unclear,” but says it is also prudent to assume that there is no viable path to market, so it removed troriluzole from its model. The firm trimmed its view of the odds of success for Kv7 by about 20% as today’s setback “calls into question the trust-factor on dose interrogation with that agent,” the analyst tells investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHVN:
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!
- Midday Fly By: Broader market bought on dip after tech selloff
- Biohaven Ltd.: Strategic Initiatives and Financial Positioning Drive Buy Rating Amid FDA Challenges
- Biohaven downgraded to Market Perform from Outperform at William Blair
- Biohaven trading resumes